Auspherix Raises £6Million to Progress its Novel Antibiotics and Establishes UK Operations
In the race to develop new antibiotics with completely new modes of action that might address the growing threat posed by antimicrobial resistance, Auspherix Limited (UK), an early stage anti-infectives company originated in Sydney Australia, has raised £6 million in a Series A venture financing, and is establishing operations on the Stevenage Bioscience Catalyst site just outside of London, UK. New investor Imperial Innovations plc led the round alongside Australian founding investor the Medical Research Commercialisation Fund (MRCF).
The investment will be used to fund the Company’s drug discovery programme, expand the experienced management team and recruit a world-class microbiology team. Auspherix aims to progress its novel class of antibacterials, which have a unique profile and novel mechanism of action, through lead optimization to final candidate selection within the next two years. Auspherix’s current lead compounds show activity against a broad range of multidrug resistant (MDR) important Gram-negative and Gram-positive bacterial infections.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Altea Therapeutics and the CDC sign agreement for evaluating novel approaches to the delivery of influenza vaccines - Delivery of influenza antigens to immune cells near the skin surface
Neovacs acquires Interferon Alpha manufacturing technology from AMEGABIOTECH
Roche goes on shopping spree - Billion euro purchase for stomach medicine
Genzyme Concludes Treat-to-Goal Study
Method developed by VTT targets diagnosis of early Alzheimer’s disease - Half of patients could be diagnosed a year earlier than current clinical practice
Ablynx announces an extension of its global strategic nanobody alliance with Boehringer Ingelheim
Embryonic development and cancer cell growth - Embryonic factors for reprograming cancer cells
Genzyme’s Mozobil Shows Promise in Chemosensitization
Cornell geneticists improve methods for identifying what controls complex traits
BioImage A/S - Søborg, Denmark
Breaking the coupling process - Real-time observation of signal transmission in proteins provides new insights for drug research
